John Ford (Enterprise)

Roche joins Ab­b­Vie in step­ping on Ver­tex's turf, bet­ting $96M on an al­ter­na­tive CF ap­proach

James Sabry’s lat­est deal spree is tak­ing Roche back to a field where Genen­tech nabbed one of its first FDA ap­provals: cys­tic fi­bro­sis.

Turn­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.